The University of Minnesota has launched a cell therapy research initiative for autoimmune diseases. The initiative brings together experts from across varying specialties creating a multidisciplinary team to provide innovative cell therapy clinical trial options to patients. Some of trials that are currently open to enrollment target the following diseases; systemic sclerosis, idiopathic inflammatory myopathies, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. 

At the University of Minnesota, we are at the forefront of advancing cell therapy research for autoimmune disorders. Our mission is to lead clinical innovation in cell therapy for autoimmune diseases and to provide clinical trials that improve the lives of patients affected by these complex conditions.

Building on a decade of experience in CAR-T therapy for cancer treatment, our team is focused on translating these groundbreaking technologies to address autoimmune diseases. Through close collaboration with leading experts and community healthcare partners, we are committed to advancing cell-based therapies and focused on bringing innovative treatment options to patients in the Twin Cities, Greater Minnesota, and beyond.